MedscapeSeptember 9, 2026Safety
Tirzepatide Beats Semaglutide for Weight Loss, Not Safety
Reported by Medscape. Read the original →
What the story says
The headline reports that Tirzepatide is more effective than Semaglutide for weight loss, but does not indicate a difference in safety between the two compounds.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
SemaglutideA · Human clinical
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
TirzepatideA · Human clinical
- Clinical performance of monolithic and veneered zirconia three-unit posterior FDPs: A five-year multicenter randomized controlled trial.Human · RCT · 2026
- Insights from a double-blind, randomized, direct-to-participant intervention trial for Long COVIDHuman · RCT · 2026
- Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Human · RCT · 2026
What the headline doesn't tell you
- Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
- Tirzepatide has 29 studies on file, 16 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.